Evgeny Lvovich Nasonov, Academician of the Russian Academy of Sciences, director of the V.A. Nasonova Research Institute of Rheumatology, editor-in-chief of the journal “Rheumatology Science and Practice.”
E.L. Nasonov was born in 1948. He graduated from the I.M. Sechenov First Moscow State Medical University in 1972. E.L. Nasonov is a Doctor of Medical Sciences (1986), professor specializing in internal medicine (1991), academician of the Russian Academy of Sciences, and honored scientist of the Russian Federation.
Since 1991, he has been heading the Rheumatology Division (Department of Postgraduate Education, I.M. Sechenov First Moscow State Medical University) and has been the director of the V.A. Nasonova Research Institute of Rheumatology since 2001.
E.L. Nasonov is an author to 453 publications, including 15 monographs.
His research interests include the interdisciplinary problems of rheumatology and immunopathology of human diseases.
E.L. Nasonov has conducted a series of integrated studies that provided new findings about the immunity disorders in patients with inflammatory rheumatic diseases, which contributed to the development of modern research concepts of the immunoinflammatory nature of these diseases. Fundamentally new trends of research are being developed, focused on the modern approaches to early diagnosis and anti-inflammatory therapy of rheumatic diseases, osteoporosis prevention and treatment, the role of immune disorders in the development of cardiovascular pathology using inflammatory rheumatic diseases as a model.
E.L. Nasonov has been an academic supervisor of 10 future doctors of medicine and 45 candidates of medical sciences who have successfully defended their theses.
E.L. Nasonov is the chairman of the specialized dissertation board for the rheumatology specialization, the chairman of the Expert Council of the Ministry of Healthcare of the Russian Federation for the rheumatology specialization, deputy chairman of the Formulary Committee of the Ministry of Healthcare of the Russian Federation, the president of the Russian Association of Rheumatologists, a member of the Board of Moscow Municipal Research Therapeutic Community, a member of the American College of Rheumatologists and the editorial board of journals “Vestnik RAMN” (Bulletin of the Russian Academy of Medical Sciences), “Clinical Medicine” and the international journal of the European League against Rheumatism (EULAR) “Clinical Rheumatology”.
Since 2009, Academician E.L. Nasonov has been the editor-in-chief of the journal “Rheumatology Science and Practice”. The first decade of the XXI century is associated with revolutionary advances in rheumatology. Of course, this fact contributed to new trends in research and new sections have appeared in the journal.
Verification of the role of inflammatory mechanisms in development of atherosclerosis involving cytokines and other inflammation mediators, which play a key role in pathogenesis of rheumatic diseases, was an incentive for in-depth studying the cardiovascular disorders, the incidence and mechanisms of development of early atherosclerosis (in particular, in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The results of clinical trials of novel hi-tech biologic agents (first of all, tumor necrosis factor α inhibitors, anti-B cell agents, inhibitors of T cell co-stimulation and interleukin 6 receptors) are regularly published in the journal.
On the initiative of E.L. Nasonov, the discipline-specific “RADICAL” program focused on studying the clinical and diagnostic features, outcomes and principles of RA treatment at early stages, during the therapeutic window of opportunity when treatment has the highest effect, has been developed. This type of studies is also conducted at early stages of other rheumatic diseases (juvenile arthritis, ankylosing spondylitis, SLE, etc.). The results of these studies are also reported in the articles published in the journal.
The editor-in-chief pays considerable attention to covering the questions associated with innovation technologies focused on improvement of early laboratory immunodiagnosis of RA and SLE, studying the molecular genetic mechanisms of inflammation, using immunological markers to evaluate the effectiveness of therapy with biological agents, predicting the course of rheumatic diseases, and searching for laboratory biomarkers of cardiovascular risk in patients with these diseases.
The results of innovative studies focused on gout, which is discussed within the concept of the metabolic syndrome; fundamental studies focused on the role of precursor cells in pathological angiogenesis in patients with systemic scleroderma (SSD), clinical significance of anti-nucleosome and anti-heat shock protein antibodies in SLE, quantitative and qualitative determination of the composition of extracellular DNA and role in the development of autoimmune and immunoinflammatory responses, etc. are also published in the journal.
E.L. Nasonov places great emphasis on elaboration of modern standards of diagnosis and treatment for rheumatic patients, which are published in the journal as clinical recommendations. These recommendations are published under the auspices of the Russian Association of Rheumatologists and are widely distributed among rheumatologists and other doctors. The recommendations have become a reference book for several thousand physicians all over Russia and allow them to use the modern and scientifically justified diagnosis and therapy methods to treat their patients at the local level.
The journal “Rheumatology Science and Practice”, headed by its editor-in-chief E.L. Nasonov, Academician of the RAS, remains the main research periodical for all Russian rheumatologists. His weight among foreign researchers, the members of the European League against Rheumatism (EULAR), who are the members of the editorial board of the journal, is also high.
